VINCRISTINE BY CONTINUOUS INFUSION IN REFRACTORY BREAST-CANCER - A PHASE-II STUDY
- 1 January 1983
- journal article
- research article
- Vol. 6 (5) , 529-532
Abstract
Patients (18) with advanced refractory breast carcinoma were treated with vincristine (VCR), 0.5 mg i.v. bolus followed by continuous i.v. infusoins of 0.25 mg/m2 per day for 5 days every 3 wk. The daily dose of VCR was infused in 1000 ml D5W [5% dextrose in water] to which was added hydrocortisone 50 mg and heparin 3000 U. Patients received 1-6 courses (mean 2.3 courses). No objective responses were observed. Stable disease was noted in 5 patients who had skeletal metastases only. Disease progression occurred in the remaining 13 patients, 10 of whom had received prior VCR by bolus injection. The principal toxicity consisted of constipation without ileus and hyporeflexia-paresthesias. VCR administered by continuous i.v. infusion according to this dose and schedule does not appear to be effective in the treatment of patients with advanced refractory breast cancer.This publication has 5 references indexed in Scilit:
- Intravenous vincristine infusion: Phase I trialCancer, 1981
- PHARMACOKINETICS OF VINCRISTINE SULFATE IN ADULT CANCER-PATIENTS1981
- PHARMACOKINETICS OF VINCRISTINE INFUSION1981
- VINBLASTINE GIVEN AS A CONTINUOUS 5-DAY INFUSION IN THE TREATMENT OF REFRACTORY ADVANCED BREAST-CANCER1980
- CYTOTOXIC THRESHOLDS OF VINCRISTINE IN A MURINE AND A HUMAN-LEUKEMIA CELL-LINE INVITRO1979